Business Performance - Filled VOQUEZNA prescriptions have exceeded 580,000 since launch, compared to over 390,000 as of April 18, 2025[9] - Quarterly filled prescriptions reached approximately 173,000 in Q2 2025, a roughly 36% increase from the previous quarter[10] - Cumulative writers have surpassed 29,300 as of July 18, 2025, up from over 23,600 as of April 11, 2025[13] - Gastrointestinal (GI) specialists account for 70% of the launch-to-date volume, while Primary Care Physicians (PCP) and other non-GI specialties make up 30%[17] - The company is increasing calls on approximately 37,000 Healthcare Professionals (HCPs), focusing on nearly all GIs, all existing writers, and high decile PCPs in Q3 2025[18] Financial Results and Guidance - The company had $1496 million in cash and cash equivalents as of June 30, 2025[28] - The company anticipates reaching profitability in 2026[28] - Net revenue for FY 2025 is projected to be between $165 million and $175 million[22] - Non-GAAP operating expenses are forecasted to be less than $60 million for Q3 2025 and less than $55 million for Q4 2025[22] - Quarterly net revenue increased from $73 million in Q2 2024 to $395 million in Q2 2025[31]